[ARS] PROTHENA CORP PUBLIC LTD CO SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

ARS

03/27/2026 - 04:20 PM

ARS - PROTHENA CORP PUBLIC LTD CO

ARS Filing - PROTHENA CORP PUBLIC LTD CO

This filing is available as a PDF document.

Filing Type: ARS

Company: PROTHENA CORP PUBLIC LTD CO (PRTA)

Acceptance Date: 2026-03-27T16:20:23.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Prothena

NASDAQ:PRTA

View PRTA Stock Overview →

PRTA Rankings

#3418 Ranked by Market Cap

N/A Ranked by Dividends

PRTA Latest News

Mar 21, 2026

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Mar 9, 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Feb 27, 2026

Prothena Announces up to $100 Million Share Repurchase Plan

Feb 19, 2026

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 12, 2026

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

PRTA Latest SEC Filings

Mar 27, 2026

[DEF 14A] PROTHENA CORP PUBLIC LTD CO Definitive Proxy Statement

Mar 5, 2026

[Form 4] PROTHENA CORP PUBLIC LTD CO Insider Trading Activity

Mar 5, 2026

[Form 4] PROTHENA CORP PUBLIC LTD CO Insider Trading Activity

Mar 5, 2026

[Form 4] PROTHENA CORP PUBLIC LTD CO Insider Trading Activity

Mar 5, 2026

[Form 4] PROTHENA CORP PUBLIC LTD CO Insider Trading Activity

PRTA Stock Data

Market Cap 512.49M

Float 43.39M

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country Ireland

City DUBLIN 2